Moderna 与 Merck 推进个体化黑色素瘤疗法上市申报,COVID 疫苗销售提振 Q3
Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3
Moderna 在 11 月 6 日的财报中表示,正准备为其与 Merck 联合开发的个体化癌症疫苗 intismeran autogene 寻求批准。该疗法基于每位患者肿瘤突变选择最多 34 个新抗原,编码进个体化 mRNA 疫苗,与 Keytruda 联用。
材料给出个体化癌症疫苗的注册推进节奏与三期数据,读者可据此了解该联合疗法的疗效与安全性边界。
Moderna is preparing to seek approval for intismeran autogene, the personalized cancer vaccine it is developing with Merck, according to its November 6 earnings release. The therapy could open a new source of revenue beyond the infectious disease vaccines that built its business.
Investor enthusiasm has rebounded as the cancer program has advanced. Moderna shares have climbed more than 700% this year, a rally Barron’s attributes to excitement over the experimental vaccine.
As COVID-19 vaccine demand receded, Moderna’s annual revenue fell roughly 90%, from $19.3 billion in 2022 to $1.9 billion in 2025.
The oncology program predates Moderna’s pandemic boom. Moderna and Merck began collaborating in 2016, and their Phase 2b melanoma study began enrolling patients in 2019. Merck paid $250 million in 2022 to exercise its option to jointly develop and commercialize the therapy. The partners share development costs and any profits equally.
Intismeran is designed to help prevent melanoma from returning after surgery. Each patient’s tumor mutations guide the selection of up to 34 targets, called neoantigens, encoded in an individualized mRNA vaccine. The aim is to direct T cells toward cancer cells, while Keytruda blocks a signal that can suppress those immune cells.
The Phase 3 INTerpath-001 trial tested the combination in 1,137 patients whose high-risk melanoma had been surgically removed. Results presented at ESMO showed that adding intismeran reduced the risk of recurrence or death by 42% compared with Keytruda alone. At two years, 82.2% of combination recipients were alive without recurrence, compared with 70.0% in the control group.

A prespecified sensitivity analysis found a 58% risk reduction during the period after six months, following the immunization regimen. The primary 42% result covers the full follow-up period. Grade 3-5 treatment-related adverse events occurred in 14.2% of combination recipients and 13.4% of the control group. The trial continues to track overall survival.
The partners are also testing the approach in other cancers. In a November 6 research note, UBS analysts Michael Yee, Dina Elmonshed and Kyle Yang identified kidney and bladder cancer results as the next two key readouts for Moderna shares. The wider program also includes three Phase 3 lung cancer trials.
Beyond oncology, Moderna expects pivotal results this year for mRNA-3927, its experimental treatment for propionic acidemia. Its norovirus vaccine program faces a setback: after an interim analysis fell short of the threshold for early success, the company dropped plans to add a trial cohort this season and will consult health authorities on the program’s path forward.
Filed Under: Infectious Disease
Brian Buntz
As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.
Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].
来源:Drug Discovery & Development · drugdiscoverytrends.com